<DOC>
	<DOC>NCT00320398</DOC>
	<brief_summary>This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).</brief_summary>
	<brief_title>Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)</brief_title>
	<detailed_description />
	<mesh_term>Thromboembolism</mesh_term>
	<mesh_term>Venous Thromboembolism</mesh_term>
	<mesh_term>Fondaparinux</mesh_term>
	<mesh_term>PENTA</mesh_term>
	<criteria>Patients undergoing either an elective primary THR (total hip replacement) surgery or a revision of a THR. Active, clinically significant bleeding (excluding drainage).</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>Fondaparinux</keyword>
	<keyword>MOSLL</keyword>
	<keyword>THR</keyword>
	<keyword>VTE</keyword>
	<keyword>Xa factor</keyword>
	<keyword>pentasaccharide</keyword>
	<keyword>Hip Replacement Arthroplasty</keyword>
</DOC>